dMed

Acquired

临床研究服务供应商 | 临床研究解决方案 - 康缔亚

Shanghai, China · Founded 2016 · $200.0M raised

Headquarters
Shanghai
Employees
501–1000
Founded
2016
Business Model
B2B
Total Funding
$200.0M
Last Round
$50.0M Series CJul 2021
Rounds
5

About

dMed Biopharmaceutical Co., Ltd. (now operating as Caidya following its 2021 merger with Clinipace) was a full-service clinical contract research organization (CRO) founded in 2016 in Shanghai, China by Dr. Lingshi Tan, a former Pfizer executive. The company grew to nearly 700 professional staff and specialized in strategic consultation, clinical operations, biostatistics, pharmacovigilance, and regulatory affairs, serving pharma and biotech clients across China and globally. In 2021, dMed merged with US-based Clinipace to form Caidya, a combined global CRO with nearly 1,800 employees operating in more than 30 countries.

Summary

dMed is a Healthcare company based in Shanghai, China, founded in 2016. It has raised $200.0M in total across 5 rounds, most recently a $50.0M Series C round in Jul 2021. Investors include Fidelity Management, Qiming VP and Lilly Asia Ventures.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CJul 2021
$50.0M

Sign up to see all 5 rounds

Angel through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

dMed on Indexed.vc
<a href="https://indexed.vc/companies/dmed"><img src="https://indexed.vc/api/badge/company/dmed" alt="dMed on Indexed.vc" width="260" height="76" /></a>